Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease by Castro, Andreia Cristiana Teixeira et al.
Serotonergic signalling suppresses ataxin 3
aggregation and neurotoxicity in animal models
of Machado-Joseph disease
Andreia Teixeira-Castro,1,2,3,4,* Ana Jalles,1,2,* Sofia Esteves,1,2,* Soosung Kang,3,5,6
Liliana da Silva Santos,1,2 Anabela Silva-Fernandes,1,2 Ma´rio F. Neto,3,4 Rene´e
M. Brielmann,3,4 Carlos Bessa,1,2 Sara Duarte-Silva,1,2 Adriana Miranda,1,2
Ste´phanie Oliveira,1,2 Andreia Neves-Carvalho,1,2 Joa˜o Bessa,1,2 Teresa Summavielle,7
Richard B. Silverman,3,5,6 Pedro Oliveira,8 Richard I. Morimoto3,4 and Patrı´cia Maciel1,2
*These authors contributed equally to this work.
Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here
we provide evidence that activation of serotonergic signalling is beneﬁcial in animal models of Machado-Joseph disease. We identiﬁed
citalopram, a selective serotonin reuptake inhibitor, in a small molecule screen of FDA-approved drugs that rescued neuronal
dysfunction and reduced aggregation using a Caenorhabditis elegans model of mutant ataxin 3-induced neurotoxicity. MOD-5,
the C. elegans orthologue of the serotonin transporter and cellular target of citalopram, and the serotonin receptors SER-1 and SER-4
were strong genetic modiﬁers of ataxin 3 neurotoxicity and necessary for therapeutic efﬁcacy. Moreover, chronic treatment of
CMVMJD135 mice with citalopram signiﬁcantly reduced ataxin 3 neuronal inclusions and astrogliosis, rescued diminished body
weight and strikingly ameliorated motor symptoms. These results suggest that small molecule modulation of serotonergic signalling
represents a promising therapeutic target for Machado-Joseph disease.
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Introduction
The expansion of trinucleotide CAG repeats causes hereditary
adult-onset neurodegenerative disorders such as Huntington’s
disease, spinobulbar muscular atrophy, dentatorubral-
pallidoluysian atrophy and six forms of spinocerebellar
ataxia (Ross et al., 1998). Machado-Joseph disease (or spino-
cerebellar ataxia type 3, SCA3), the most common dominantly
inherited SCA worldwide (Schols et al., 2004), is characterized
by ataxia, ophthalmoplegia and pyramidal signs, associated
with dystonia, spasticity, peripheral neuropathy and amyot-
rophy (Coutinho and Andrade, 1978), without cognitive de-
cline. Pathologically, there is degeneration of the deep nuclei of
the cerebellum, pontine and subthalamic nuclei, substantia
nigra and spinocerebellar nuclei. The genetic basis of
Machado-Joseph disease is the expansion of a polyglutamine
tract within the protein ataxin 3 (ATXN3) (Kawaguchi et al.,
1994). When the polyglutamine tract exceeds 60 consecutive
glutamines, ATXN3 becomes highly aggregation prone, lead-
ing to an imbalance in cellular proteostasis, as aggregation-
associated proteotoxicity dominates over folding and clearance
(Balch et al., 2008; Morimoto, 2008).
Currently there is no treatment for Machado-Joseph dis-
ease that effectively slows disease progression. Efforts to im-
prove patient quality of life and to sustain independence
address the restless legs and extrapyramidal syndromes,
treatment of cramps and of the effects of fatigue (D’Abreu
et al., 2010). Not yet translated to clinical practice are thera-
peutic strategies that include the use of small molecules or
gene targeting to manipulate the concentration, conform-
ation, and/or location of ATXN3. For example, it is
known that modulating the levels of molecular chaperones
Hsp70, alphaB-crystallin and Hsp104 could prevent or in-
hibit ATXN3 aggregation, and promote its disaggregation
(Warrick et al., 2005; Robertson et al., 2010; Cushman-
Nick et al., 2013). Treatment with Hsp90 inhibitors that
increase chaperone expression had beneﬁcial effects, al-
though it failed to achieve the predicted molecular effect of
chaperone induction in animal models of Machado-Joseph
disease (Silva-Fernandes et al., 2014). Likewise, activation of
autophagy, either genetic or pharmacological, lessened
ATXN3 pathogenesis in vivo (Menzies et al., 2010;
Nascimento-Ferreira et al., 2013). In rodents, reversion of
the expanded polyglutamine-associated transcription down-
regulation by a histone deacetylase (HDAC) inhibitor res-
cued ataxic symptoms (Chou et al., 2011). Dantrolene
administration (targeting intracellular calcium homeostasis)
improved motor performance and prevented neuronal loss
(Chen et al., 2008). While silencing of ATXN3 offers poten-
tial, the impact of this type of treatment to date has not been
promising in Machado-Joseph disease mice (Costa Mdo
et al., 2013; Nobrega et al., 2013). For many proposed
therapies, translation into clinical practice will be further
limited by human safety. The traditional approach to
drug discovery, which involves de novo identiﬁcation
and validation of new molecular targets, is costly and
time-consuming, thus limiting the number of new drugs
introduced into the clinic (Shim and Liu, 2014). Moreover,
as the average time required for drug development continues
to increase, there has been renewed interest in drug repur-
posing strategies (Chong and Sullivan, 2007; Shim and Liu,
2014). On the other hand, in past years, the primary cause
of new drug candidate failures has been low therapeutic ef-
ﬁcacy in clinical trials. Among the most frequently proposed
reasons for this shortcoming is the lack of translation of
in vitro and recombinant drug activity to therapeutic
in vivo whole organism systems. As an approach to identify
novel therapeutic strategies, we used Caenorhabditis elegans
(C. elegans), a powerful platform to model neurodegenera-
tive disease and for characterization of small bioactive mol-
ecules (Kaletta and Hengartner, 2006). Previously, we
established a C. elegans model for Machado-Joseph disease
pathogenesis in which expression of mutant ATXN3 in the
nervous system led to its progressive aggregation in distinct
neuronal subtypes and altered motor behaviour (Teixeira-
Castro et al., 2011a). Here, we used this model to screen
a library of FDA-approved small molecules, and identiﬁed
compounds that rescued or ameliorated mutant ATXN3-
mediated neurological dysfunction. By combining compound
treatment with genetic tools, we demonstrate that modula-
tion of serotonergic signalling by selective serotonin reuptake
inhibitors (SSRIs) suppressed mutant ATXN3 aggregation
and neurotoxicity in both C. elegans and mice. This reveals
the utility of the approach by which safe and highly effective
bioactive small molecules can be repurposed to beneﬁt rare
diseases lacking effective therapies. The ﬁnding that sero-
tonin recapture inhibition modulates proteotoxicity may be
relevant for other protein conformation disorders.
Materials and methods
Study design
The overall objective of the study was to ﬁnd novel therapeutic
targets for Machado-Joseph disease. The ﬁrst part of this study
was designed to identify novel suppressor compounds of
mutant ATXN3 pathogenesis in vivo, using a hypothesis-free
approach. The second aim of the study was to validate one of
the identiﬁed drugs in a vertebrate model of the disease. To
achieve the two goals, a small molecule screening of a FDA-
approved library was conducted using a transgenic C. elegans
model of the disease (Teixeira-Castro et al., 2011a). The most
promising hit of the screening regarding human safety, target
speciﬁcity and conservation across evolution was tested in
CMVMJD135 mice (Silva-Fernandes et al., 2014). For all
animal experiments, we ensured blinded outcome assessment.
Experimental design was based on power analyses for opti-
mization of sample size. C. elegans (Supplementary Table 1)
and mice (Supplementary Table 2) sample size calculations
were performed for each behavioural test and pathological
analyses assuming a power of 0.95 and 0.8, respectively, and
a signiﬁcance level of P5 0.05. The effect size was calculated
aiming for a 50% improvement. In general, we used n = 3–4
2 | BRAIN 2015: Page 2 of 17 A. Teixeira-Castro et al.
 by guest on Septem
ber 17, 2015
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
per genotype/treatment of C. elegans for motility assays, n = 8–
14 for aggregation (with three replicates) and n = 4 for im-
munoblotting. For mice, we used n = 13–16 per genotype/treat-
ment for behavioural tests, and a group size of four animals
per group for quantiﬁcation of ATXN3 intranuclear inclu-
sions, assessment of astrogliosis and western blot analysis.
All experiments were designed with commitment to the prin-
ciples of reﬁnement, reduction, and replacement and per-
formed according to the FELASA guidelines to minimize
discomfort, stress, and pain to the animals, with deﬁned
humane endpoints (1994).
Nematode strains and general
methods
For a list of strains used in this work and abbreviations, see
Supplementary Table 3. All the strains were backcrossed to
Bristol strain N2 ﬁve to eight times. Standard methods were
used for culturing and observing C. elegans, unless otherwise
noted (Brenner, 1974). Nematodes were grown on nematode
growth medium plates seeded with Escherichia coli OP50
strain at 20C.
Compounds
All the compounds were obtained from the commercial vendors
indicated below and were used without further puriﬁcation. The
Prestwick Chemical LibraryTM (Prestwick Chemical) used for
the C. elegans screening comprised 1120 chemical and pharma-
cologically diverse small molecules. Other compounds used,
including the 11 hits selected for validation, were reordered
from a different manufacturer before repetition of experiments:
17-(allylamino)-17-demethoxygeldanamycin (17-AAG) CAS
75747-14-7 (Biomol); nisoxetine hydrochloride CAS 57754-
86-6 (Sigma); scoulerine CAS 6451-73-6 (Toronto Research);
eburnamonine CAS 4880-88-0 (Santa Cruz); piperlongumine
CAS 20069-09-4 (Biotrend); chlortetracycline hydrochloride
CAS 64-72-2 (Sigma); tiapride hydrochloride CAS 51012-33-0
(Sigma); clemizole hydrochloride CAS 1163-36-6 (Sigma);
metixene hydrochloride CAS 7081-40-5 (Sigma); budesonide
CAS 51333-22-3 (Sigma); noscapine CAS 128-62-1 (Sigma); es-
trone CAS 53-16-7 (Sigma); ﬂuoxetine CAS 56296-78-7
(Kemprotec Ltd.); zimelidine CAS 61129-30-4 (Sigma); lyzergol
CAS 602-85-7 (Sigma); pindolol CAS 13523-86-9 (Sigma); tra-
zodone hydrochloride CAS 25332-39-2 (Sigma); citalopram
hydrobromide CAS 59729-32-7 (Kemprotec Ltd.); escitalopram
(S-citalopram) hydrobromide CAS 219861-08-2 (Kemprotec
Ltd). Citalopram used for studies in mice and vabicaserin
were kindly provided by Lu¨ndbeck.
Drug toxicity assay
Bristol strain N2 was used to screen the Prestwick Chemical
LibraryTM for compound toxicity. The assay was performed in
96-well plate format, in liquid culture (Voisine et al., 2007). Each
well contained a ﬁnal volume of 60ml, comprising 20–25 animals
in egg stage, drug at the appropriate concentration and OP50
bacteria to a ﬁnal OD595 of 0.6–0.8 measured in the microplate
reader (Bio-Rad microplate reader 680). To obtain the age syn-
chronized population of eggs, gravid adults were treated with
alkaline hypochlorite solution (0.5M NaOH, 2.6% NaClO)
for 7min. The animals were then washed in M9 buffer, resus-
pended in S-medium to the appropriate egg number and trans-
ferred into the 96-well plate. The OP50 bacteria were grown
overnight at 37C and 150 rpm in Luria Broth (LB) media, pel-
leted by centrifugation, inactivated by four to six cycles of freeze/
thawing, frozen at 80C and then resuspended in S-medium
supplemented with cholesterol, streptomycin, penicillin and nysta-
tin (Sigma). Worms were grown with continuous shaking at
180 rpm at 20C (Shel Lab) for 7 days. The compound library
was prepared in 100% dimethyl sulphoxide (DMSO, Sigma) and
tested at dilutions corresponding to a maximum concentration of
1% DMSO to avoid solvent-speciﬁc developmental defects and
toxicity. For each compound, two ﬁnal concentrations were
tested (50mM and 25mM). The effect of compounds on
C. elegans physiology was monitored by the rate at which the
E. coli food suspension was consumed, as a read out for
C. elegans growth, survival or fecundity. The absorbance
(OD595) was measured daily. OP50-only (S-medium, no vehicle),
DMSO 1% (vehicle) and DMSO 5% (toxic condition) controls
were used.
C. elegans assays for motility defects
and aggregation
Wild-type (WT, N2), wild-type ATXN3 (AT3WT) and mutant
ATXN3 (AT3q130) animals were grown in liquid culture in a
96-well plate format, with the chemical compounds, as
described above. Four-day-old animals were transferred from
the 96-well plates onto an unseeded nematode growth
medium plate (equilibrated at 20C). Plates were allowed to
dry for 1h before starting the assays. Motility assays were per-
formed at 20C as previously described (Gidalevitz et al., 2006;
Teixeira-Castro et al., 2011a). Motor behaviour assays were run
in triplicates or quadruplicates (n = 3 or 4), with a total of at
least 150 animals tested per genotype and/or compound. For
confocal dynamic imaging and quantiﬁcation of ATXN3 aggre-
gation, live animals were immobilized with 3mM levamisole
(Sigma) and mounted on a 3% agarose pad. All images were
captured on an Olympus FV1000 (Japan) or Zeiss LSM 510
(Germany) confocal microscopes, under a 60 oil (NA = 1.35)
or 63 water (NA = 1.0) objectives. Z-series imaging was
acquired for all vehicle- and compound-treated animals, using
a 515/514nm laser excitation line for yellow ﬂuorescent protein
fusion proteins. The pinhole was adjusted to 1.0 Airy unit of
optical slice, and a scan was acquired every 0.5mm along the
z-axis. The quantiﬁcation of the aggregates was performed as
previously described (Teixeira-Castro et al., 2011a, b). Three
parameters were measured: area of aggregates/total area;
number of aggregates/total area; and number of aggregates.
Values shown are the mean (normalized to vehicle treated con-
trol) of eight or more animals per group, unless noted otherwise.
Chemical and pharmacological
classification of the hits
Hits were manually inspected to categorize them into chemical
and pharmacological classes based on MeSH tree (Medical
Subject Headings; PubMed), ChEBI Ontology (Chemical
Entities of Biological Interest), and ATC (Anatomical
Therapeutic Chemical) fourth level classiﬁcations. The major-
ity of the hits were sorted into heterocyclic, alkaloid, steroid,
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polycyclic, and b-amino alcohol chemical classes, and further
classiﬁed into neurotransmitter, anti-infective, cardiovascular,
anti-inﬂammatory, analgesic, and hormone pharmacological
classes. For a drug that has multiple therapeutic applications,
all classes were equally considered. However, if a new multi-
therapeutic drug shares the same structural and pharmaco-
logical class with a high scored single therapeutic compound,
we considered only a single therapeutic application and clus-
tered the new molecule into the same class. This classiﬁcation
allowed us simple observation of the chemical and pharmaco-
logical classes of the hits.
C. elegans citalopram time course
assays
For time course experiments, animals were grown on nematode
growth medium plates with OP50 supplemented with citalo-
pram. OP50 cultures were prepared as described above and
concentrated 10 with S-media supplemented with strepto-
mycin, penicillin and nystatin (Sigma). Stock solutions of citalo-
pram (2.5mM and 0.5mM) (Kemprotec) or vehicle (DMSO)
were prepared and added to OP50 cultures to a ﬁnal concen-
tration of 25mM or 5mM. Plates were seeded with 200ml of
OP50-citalopram/vehicle and left at room temperature to dry
for at least 3 days. Fresh plates were prepared two to three
times a week to prevent drug degradation. OFF-drug effect
was evaluated by treating the animals for 4 days and after
that time animals were transferred to DMSO plates (vehicle),
shown in Fig. 2D as AT3q130::cit OFF. During the reproductive
period, animals were transferred into new fresh plates every day.
Immunoblotting analysis
For determination of the steady-state protein levels of ATXN3,
the animals were incubated in liquid culture with the chemical
compounds in a 96-well plate format as described above. Four-
day-old animals were transferred from the liquid culture onto
an unseeded nematode growth medium plate (equilibrated at
20C). After 1 h of acclimation 25 individual young adult ani-
mals were picked, boiled for 15min in sodium dodecyl sul-
phate (SDS) sample buffer (to destroy all the aggregates) and
the resulting extracts resolved on a 10% SDS gel, as previously
described (Gidalevitz et al., 2009; Teixeira-Castro et al., 2011).
Immunoblots were probed with anti-ATXN3 mouse (1H9,
MAB5360, Milipore; 1:1000 or 1:150) and anti-tubulin
mouse antibodies (T5168, Sigma; 1:5000); and detected with
horseradish peroxidase-coupled secondary antibodies (Bio-
Rad) and chemiluminescence (ECL western-blotting detecting
reagents, Amersham Pharmacia). Protein isolation from mouse
brainstem tissue and western blot were performed as previ-
ously described (Silva-Fernandes et al., 2010). The blots were
blocked and incubated overnight at 4C with the primary anti-
body rabbit anti-ataxin 3 serum (kindly provided by Dr Henry
Paulson) (1:5000) and mouse anti-GAPDH (G8795, Sigma,
1:1000). As a loading control, mouse ataxin 3 and GAPDH
were used. Western blot quantiﬁcations were performed using
Chemidoc XRS Software with ImageLab Software (Bio-Rad)
or ImageJ software (NIH), according to the manufacturer’s
instructions. ATXN3 fractionation assays were performed as
previously described (Koch et al., 2011), with the following
modiﬁcations: AT3q130 animals were grown for 4 days in
nematode growth medium-citalopram/vehicle plates.
Nematodes were collected and washed in M9 buffer, and re-
suspended in RIPA buffer [50mM Tris, 150mM NaCl, 0.2%
Triton
TM
X-100, 25mM EDTA, supplemented with complete
protease inhibitor (Roche)] before shock freezing in liquid ni-
trogen. After three freeze-thawing cycles, the worm pellet was
ground with a motorized pestle, and lysed on ice, in the pres-
ence of 0.025 U/ml benzonase (Sigma). The lysate was centri-
fuged at 1000 rpm for 1min in a table-top centrifuge to pellet
the carcasses (Nussbaum-Krammer et al., 2013). Protein con-
centration was determined using Bradford assay (Bio-Rad) and
was set to a ﬁnal concentration of 3–4 mg/ml in all experimental
conditions and followed by a 22000 g centrifugation for
30min at 4C. The pellet fractions were separated from super-
natants (Triton
TM
X-100-soluble fraction) and homogenized in
150ml RIPA buffer containing 2% SDS followed by a second
centrifugation step at room temperature. The supernatants
(SDS-soluble fraction) were removed, and the remaining pellets
were incubated for 16h in 100% formic acid at 37 C. After
formic acid evaporation at 37C, the pellet was dissolved in
25 ml Laemmli buffer (SDS-insoluble fraction) followed by pH
adjustment with 2M Tris-base for SDS–polyacrylamide gel
electrophoresis analysis. Gels were loaded with 50 mg of the
Triton
TM
X-100 fraction, 40 ml of the SDS-soluble fraction
and the complete SDS-insoluble fraction. Western blot analyses
were performed as described above.
Lifespan
Assays were performed at 20C as previously described (Morley
and Morimoto, 2004). Approximately 100 hermaphrodites were
cultured on each Petri dish and were transferred to fresh plates
every day until the cessation of progeny production, and about
every 1–3 days thereafter. Animals were scored as dead if they
showed no spontaneous movement or response when prodded.
Dead animals that displayed internally hatched progeny,
extruded gonad or desiccation were excluded.
Transgenic mouse model and drug
administration
CMVMJD135 mice were generated as described previously
(Silva-Fernandes et al., 2014). DNA extraction, animal geno-
typing and CAG repeat size analyses were performed as pre-
viously described (Silva-Fernandes et al., 2010). The mean
repeat size [ standard deviation (SD)] for all mice used
was 130  2. Age-matched and genetic background-matched
wild-type animals were used as controls. Only male mice
were used in this study. We administrated citalopram hydro-
bromide CAS 59729-32-7 (Lu¨ndbeck, Denmark) in the drink-
ing water at two doses (8 and 13mg/kg/day) that roughly
equate to the high dosage range prescribed to human patients
for depression (Cirrito et al., 2011). Treatment was initiated at
5 weeks of age, one week before the expected onset of the ﬁrst
neurological symptoms. The trial was ended at 34 weeks of
age, according to the humane endpoints established for the
non-treated CMVMJD135 mice. All animal procedures were
conducted in accordance with European regulations (European
Union Directive 86/609/EEC). Animal facilities and the
people directly involved in animal experiments (A.T.C., S.E.,
A.S.F., S.D.S.) were certiﬁed by the Portuguese regulatory
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entity - Direcc¸a˜o Geral de Alimentac¸a˜o e Veterina´ria. All of the
protocols performed were approved by the Animal Ethics
Committee of the Life and Health Sciences Research
Institute, University of Minho.
Neurochemical quantification
CMVMJD135 and wild-type male littermate mice (n = 5–8)
were sacriﬁced at 24 weeks of age by decapitation, their
brains were rapidly removed, snap frozen in liquid nitrogen
and dissected. Serotonin (5-HT) and 5-hydroxyindoleacetic
acid (5-HIAA) levels were measured in the substantia nigra,
medulla oblongata and cerebellum by high performance liquid
chromatography, combined with electrochemical detection
(HPLC/EC), as described previously (Santos et al., 2010).
Concentrations of neurotransmitters were calculated using
standard curves and results were expressed in terms of 5-HT
and metabolism content per amount of protein.
Behavioural assessment
Behavioural analysis was performed during the diurnal period
in groups of ﬁve males per cage including CMVMJD135 hemi-
zygous transgenic mice and wild-type littermates (n = 13–16
per genotype) treated with citalopram or with vehicle
(water). All behavioural tests started in a presymptomatic
stage (4 weeks) and were conducted until 30 or 34 weeks of
age. Neurological tests and general health assessment were
performed using the SHIRPA protocol, enriched with the
hanging wire test. The dragging of the paws and the stride
length were evaluated with footprint analysis. Motor behav-
iour was further assessed using the balance beam walk test
(12-mm square and 17-mm round beams) and the motor
swimming test. All behavioural tests were performed as previ-
ously described (Silva-Fernandes et al., 2014). Body weight
was also registered for each evaluation time point.
Immunohistochemistry and
quantification of neuronal inclusions
Thirty-four-week-old wild-type and CMVMJD135 littermate
mice, vehicle- and citalopram-treated (n = 4 for each group)
were deeply anaesthetized [a mixture of ketamine hydrochlor-
ide (150mg/kg) plus medetomidine (0.3mg/kg)] and transcar-
dially perfused with phosphate-buffered saline (PBS) followed
by 4% paraformaldehyde (Panreac). Brains were removed and
post-ﬁxed overnight in paraformaldehyde and embedded in
parafﬁn. Slides with 4-mm thick parafﬁn sections were sub-
jected to antigen retrieval and then incubated with mouse
anti-ATXN3 (1H9, MAB5360, Millipore; 1:100), rabbit anti-
GFAP (Dako Corporation; 1:1000) or rabbit anti- Calbindin
D-28K (AB1778, Millipore, 1:1000) antibodies, which were
detected by incubation with a biotinylated anti-polyvalent anti-
body, followed by detection through biotin-streptavidin
coupled to horseradish peroxidase and reaction with the
DAB (3, 30-diaminobenzidine) substrate (Lab VisionTM Ultra-
VisionTM Detection kit, Thermo Scientiﬁc). The slides were
counterstained with haematoxylin 25% according to standard
procedures. Fifty-micrometre thick vibrotome spinal cord sec-
tions were incubated with goat Anti-Choline Acetyltransferase
(ChAT, Millipore, 1:500) and stained according to
VECTASTAIN

ABC system (Vector Laboratories). Thirty-
four-week-old wild-type and CMVMJD135 littermate mice,
vehicle- and citalopram-treated (n = 4 for each group), were
deeply anaesthetized as mentioned above, transcardially per-
fused with NaCl (0.9%) and the mouse brains embedded in
O.C.T. and rapidly frozen in isopentane (Sigma, CAS#78-78-
4) chilled in liquid nitrogen. Slides with 30-mm thick cryostat
sections were incubated with anti-ChAT according to the Lab
VisionTM Ultra-VisionTM Detection kit instructions. ATXN3
positive inclusions in the pontine nuclei, reticulotegmental nu-
cleus of the pons, facial motor nucleus and lateral reticular
nucleus; stained astrocytes (GFAP-positive) in the substantia
nigra; Calbindin D-28K positive neurons in the cerebellar
cortex; ChAT-positive neurons in the facial motor nucleus
and in the ventral horn of the lumbar spinal cord of either
vehicle- or citalopram-treated animals (n = 3–4 for each condi-
tion, four slides per animal) were quantiﬁed and normalized
for total area using the Olympus BX51 stereological micro-
scope (Olympus) and the Visiopharma integrator system soft-
ware (Visopharm) as previously described (Silva-Fernandes
et al., 2014).
Statistical analysis
Data were analysed through the non-parametric Mann-
Whitney U-test when variables were non-continuous or when
a continuous variable did not present a normal distribution
(Kolmogorov-Smirnov test, P50.05). Continuous variables
with normal distributions and with homogeneity of variance
(Levene’s test) were analysed with repeated measures ANOVA
for longitudinal multiple comparisons and one-way ANOVA
or Student’s t-test for paired comparisons, using Tukey or
Bonferroni tests for post hoc comparisons. When these two
latter assumptions were not valid, an appropriate data trans-
formation (e.g. logarithmic) was applied, and the data were re-
analysed (body weight, balance beam walk test and motor
swimming test). When logarithmic data transformation did
not reduce the heterogeneity of variances (hanging wire test),
several mathematical models were applied. In this test, the best
ﬁt model was the logarithmic and the treatment differences
were analysed according the R squares of the CMVMJD135
groups, with a normal residual distribution. Statistical analysis
of C. elegans survival assays was performed using the log rank
(Mantel-Cox) test. All statistical analyses were performed
using SPSS 20.0/22.0 (SPSS Inc.) and G-Power 3.1.9.2
(University Kiel, Germany). A critical value for signiﬁcance
of P50.05 was used throughout the study.
Results
A whole animal screen identifies
small molecules that ameliorate
mutant ataxin 3-mediated neuronal
dysfunction
To identify small bioactive molecules with therapeutic value
for Machado-Joseph disease, we screened a commercially
available compound library, composed mainly of FDA/
EMA-approved drugs, using a C. elegans model of
Serotonergic signalling suppresses MJD BRAIN 2015: Page 5 of 17 | 5
 by guest on Septem
ber 17, 2015
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Machado-Joseph disease pathogenesis (AT3q130) in which
mutant ATXN3 expressed in neurons caused aggregation
and motility defects (Teixeira-Castro et al., 2011). The
strategy, validation approach and compound safety assays
are depicted in Supplementary Figs 1 and 2. In the primary
screen we identiﬁed 48 compounds (Fig. 1A) that amelio-
rated mutant ATXN3-mediated locomotion defects, show-
ing a percentage of effect to non-treated animals higher
than 50% within a conﬁdence interval of 95%
(Supplementary Fig. 3A). The hit compounds were categor-
ized into chemical and pharmacological classes based on
MeSH tree, ChEBI Ontology, and ATC fourth level classi-
ﬁcations. While the chemical structure classiﬁcation of the
hit compounds revealed marked heterogeneity, they were
enriched for speciﬁc pharmacological activities, namely
modulators of neurotransmission (adrenergic, serotonergic,
cholinergic, dopaminergic and histaminergic), anti-
infectious, cardiovascular, anti-inﬂammatory, analgesic
and hormone-related actions (Supplementary Fig. 3B).
A representative compound for each pharmacological clus-
ter (Table 1) was further assessed for safety (Supplementary
Fig. 2B) and ability to ameliorate motility impairment of
mutant ATXN3 animals (Fig. 1B). The motility of wild-
type animals was not increased by any of these hit com-
pounds, suggesting that their action is speciﬁcally targeting
mutant ATXN3-mediated pathogenesis (data not shown).
Next, we examined whether these compounds affected pro-
tein aggregation in neurons of AT3q130 animals in vivo,
and showed that the majority also decreased mutant
ATXN3 aggregation (Fig. 1C). The reduction in ATXN3
aggregation was not due to decreased steady state levels of
ATXN3 protein, suggesting a mechanism more likely related
to folding stability than enhanced clearance (Fig. 1D). In
summary, this C. elegans AT3q130 repurposing screen iden-
tiﬁed compounds with novel activity as suppressors of
ATXN3 pathogenesis.
Pharmacological and genetic
inhibition of C. elegans SERT
suppresses ATXN3 pathogenesis
Among the largest class of compounds that suppressed
mutant ATXN3-mediated pathogenesis were those that af-
fected serotonergic neurotransmission and modulated 5-HT-
mediated signalling (Fig. 1E). Of these, citalopram is a SSRI
with a proven safety record that is widely used for treatment
of depression (Mandrioli et al., 2012). The primary molecular
target of citalopram is the 5-HT transporter (SERT, encoded
by SLC6A4), which is responsible for 5-HT reuptake by ser-
otonergic neurons (Blakely et al., 1994). This target speciﬁcity
and conservation prompted us to further examine the effects
of citalopram on Machado-Joseph disease pathogenesis.
Treatment with citalopram caused complete rescue of
mutant ATXN3-mediated neuronal dysfunction (Fig. 1E),
with a dose-response proﬁle and a derived half-maximal ef-
fective concentration (EC50) value of 1mM (Supplementary
Fig. 4A). Citalopram exists as a racemic mixture but its effects
are largely due to the S-enantiomer, escitalopram; this and
other SSRIs also had beneﬁcial effects on AT3q130 animals
(Supplementary Fig. 4B). Normal behaviour and motility, de-
velopment and fecundity in wild-type animals were not af-
fected by SSRI treatment (Supplementary Fig. 4C).
Importantly, citalopram treatment signiﬁcantly reduced
mutant ATXN3 aggregation in C. elegans neurons
(Fig. 2A), and increased ATXN3 solubility (Fig. 2B), as as-
sessed by biochemical fractionation (Koch et al., 2011), with-
out affecting the overall level of protein (Fig. 2C).
On continuous exposure to citalopram, the survival of
AT3q130 animals was rescued (Supplementary Fig. 4D
and E) and their neuronal dysfunction was restored
through to Day 14 of age (Fig. 2D). This beneﬁcial effect
declined when citalopram was withdrawn, and neurotox-
icity returned after 3-4 days OFF treatment (AT3q130::cit
OFF, Fig. 2D). Maximum protection required early treat-
ment (from the egg stage through to Day 4 of adulthood)
(Fig. 2E); moreover, the extent of drug exposure period was
critical, as 2 days of treatment were insufﬁcient to exert
beneﬁcial effects (Fig. 2F).
In C. elegans, there is one 5-HT transporter orthologue
of the vertebrate SERT, MOD-5 (Ranganathan et al.,
2001). To conﬁrm the beneﬁcial effect of pharmacological
inhibition of serotonin recapture, we showed that genetic
ablation of MOD-5 rescued mutant ATXN3-mediated
motor dysfunction and aggregation in C. elegans
(Fig. 2G). Pharmacogenetic analysis also supported
MOD-5 as a cellular target of citalopram in the nematode,
as drug treatment did not further ameliorate mutant
ATXN3-mediated pathogenesis in the absence of MOD-5.
In contrast, estrone (a steroid hormone) was able to further
reduce the motility impairment of mod-5; AT3q130 ani-
mals (Fig. 2G), which is consistent with independent
modes of action for these two compounds.
The role of 5-HT receptors was examined using pharma-
cological and pharmacogenetic approaches (Fig. 3A).
Activation of postsynaptic 5-HT receptors by the 5-HT2C
receptor (HTR2C) agonist vabicaserin (Dunlop et al.,
2011) and stimulation of the presynaptic 5-HT autorecep-
tors by buspirone (Takei et al., 2005), dihydroergotamine
(Villalon et al., 2003) (Fig. 3B), lysergol (Pertz et al., 1999)
or pindolol (Corradetti et al., 1998) (Fig. 1D) ameliorated
mutant ATXN3-mediated motor dysfunction. Consistent
with this, genetic ablation of the 5-HT postsynaptic G-
protein coupled receptor SER-1 (Hamdan et al., 1999)
enhanced AT3q130 aggregation and locomotion defects
(Fig. 3C). Likewise, the effect of citalopram was also de-
pendent on these receptors. Additionally, ablation of the
SER-4 (Olde and McCombie, 1997) autoreceptor, which
by eliminating the negative feedback likely increases 5-HT
availability, restored locomotion and reduced ATXN3 ag-
gregation in vivo (Fig. 3D). Taken together, these results
support the idea that pharmacological and genetic inhib-
ition of MOD-5 restores motility and suppresses aggrega-
tion of AT3q130 through modulation of 5HTR activity.
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Figure 1 Identification of small-molecule suppressors of ATXN3 pathogenesis. (A) Graphical representation of the results of the
C. elegans-based screening in which we assessed a subset of 599 compounds of the Prestwick Chemical library. Black lines represent the mean
percentage of animals with locomotion impairment for untreated AT3q130, AT3WT and wild-type animals. Grey dots show the mean of
percentage of locomotion impaired AT3q130 animals upon treatment for each compound. The red line represents the assay cut-off to a minimum
of 50% of effect in animals’ motor behaviour. The red dot represents the percentage of locomotion impaired AT3q130 animals upon citalopram
treatment, as obtained in the primary screen. (B) Motility analysis of AT3q130 animals treated with the top 11 hit compounds found in the screen
(n = 4,  SD), **P5 0.01, ***P5 0.001 (Student’s t-test). (C) Quantification of AT3q130 aggregation by confocal imaging and fluorescence
intensity (n5 10,  SD) *P5 0.05, **P5 0.01, ***P5 0.001 (ANOVA, Bonferroni’s test). (D) Human ATXN3 expression in AT3q130 animals
treated with the top hit compounds (n = 4–6  SEM). *P5 0.05 (Student’s t-test). (E) Motility analysis of AT3q130 animals treated with com-
pounds targeting serotonergic neurotransmission found in the screen (n = 4,  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (Student’s t-test).
WT = wild-type; AT3WT = wild-type ATXN3 expressing animals; AT3q130 = mutant ATXN3 expressing animals.
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Table 1 Small molecule suppressors of ATXN3 pathogenesis grouped by their pharmacological action
Cluster Pharmacological action Drug Structure Number of hit
compounds
1 Neurotransmitter Adrenergic Nisoxetine HCl
O
N
O CH3
CH3
ClH
8
Propylamine
2 Neurotransmitter Serotonergic Scoulerine
N
OH
O
OH
O
CH3
CH3
H
Chiral 8
Alkaloid
3 Neurotransmitter Cholinergic Metixene HCl OH2
S
N
CH3
ClH
2
Heterocyclic
4 Neurotransmitter Dopaminergic Tiapride HCl
ClH
O
N
O
CH3
S
CH3
O
O
N CH3
CH3
2
Benzamide
5 Neurotransmitter Histaminergic Clemizole HCl
N
N N
Cl
ClH
3
Heterocyclic
6 Anti-inflammatory Budesonide
OCH3
O
O
OH
OH CH3
CH3
O
H
H
H
Chiral 5
Steroid
7 Cardiovascular Eburnamonine
N
N
CH3
O
H
Chiral 5
Alkaloid
8 Hormones/Hormone substituents Estrone O
CH3
OH
H
H
H
Chiral 4
Steroid
9 Analgesic Noscapine
N
O
O
CH3O
CH3
O
OO
O
CH3
CH3
HH
Chiral 2
Alkaloid
10 Anti-infective Chlortetracycline HCl ClHChiral
OH
N
OH O
OH
CH3CH3
CH3OH
O
NH2
O
Cl
OH
H
8
Polycyclic
11 Etc. Piperlongumine
O
O
CH3
O
CH3
CH3
N
OO 9
Heterocyclic
*HCl = hydrochloride.
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Citalopram treatment improves
motor balance and coordination
of CMVMJD135 mice
To further investigate the therapeutic potential of citalo-
pram, we used a transgenic mouse model of Machado-
Joseph disease, CMVMJD135, that displays progressive
Machado-Joseph disease-like motor decline and
neuropathology, including ATXN3-positive intranuclear in-
clusions in the CNS (Silva-Fernandes et al., 2014).
Although CMVMJD135 mice showed no changes in base-
line 5-HT levels measured by HPLC (Fig. 4), oral admin-
istration of citalopram (8mg/kg) to these animals (study
design; Fig. 5A) prevented their decreased body weight
gain (Fig. 5B) and had signiﬁcant beneﬁcial effects on the
motor phenotype. While there was only marginal
Figure 2 Early life chronic citalopram treatment suppressed mutant ATXN3 aggregation and neuronal dysfunction in
C. elegans. (A) Aggregate quantification in AT3q130 animals upon citalopram (cit) treatment. (B) Representative western blot analysis of ATXN3
protein upon biochemical fractionation of AT3q130 protein extracts (out of n = 3). (C) Human ATXN3 protein levels in AT3q130 cit animals. (D)
Motility of citalopram-treated wild-type (WT::cit) and AT3q130 (AT3q130::cit) animals and OFF-drug effect (AT3q130::cit OFF) as disease
progressed. (E) Motor behaviour of AT3q130 cit animals treated for 4 days, with treatment initiation at the indicated days and (F) treatment
duration for the indicated days. (G) Locomotion impairment and aggregation load of AT3q130 animals in the mod-5 background and upon treatment
with citalopram, S-citalopram and fluoxetine. For motor behaviour assays: (n = 3–4  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (Student’s t-test). For
aggregate quantification: (n5 8  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (ANOVA, Bonferroni’s test). For western blot: (n = 4  SD), P4 0.05
(Student’s t-test). TX100 = Triton
TM
X-100; FA = formic acid; cit = citalopram; S-cit = S-citalopram; fluox = fluoxetine; WT = wild-type.
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Figure 3 Serotonergic signalling improves ATXN3 pathogenesis in a G-protein coupled receptor-dependent manner. (A)
Schematic of a serotonergic synapse showing that 5-HT is synthesized and released into the synaptic cleft, where it activates postsynaptic 5-HT
receptors. Vabicaserin may activate the regulatory signalling coupled with SER-1. Pindolol, lysergol and DHE probably antagonize the 5-HT
autoreceptor SER-4, whereas the 5-HT1A receptor agonist buspirone may desensitize the receptor, shutting down the stop production signal
mediated by 5-HT autoreceptors in presynaptic neurons. (B) Motor behaviour of AT3q130 animals treated with vabicaserin, buspirone and
dihydroergotamine. (C) Motility defects and aggregation load of AT3q130 animals in a ser-1 genetic background, with and without cit, S-
citalopram and estrone treatments. (D) Motility performance and mutant ATXN3 aggregation phenotypes of AT3q130 animals in the absence of
SER-4. For motor behaviour assays: (n = 3–4,  SD), *P5 0.05, **P5 0.01, ***P5 0.001 (Student’s t-test). For aggregate quantification:
(n5 12,  SD) *P5 0.05, **P5 0.01, ***P5 0.001 (ANOVA, Bonferroni’s test). DHE = dihydroergotamine; DMSO = dimethyl sulphoxide; cit
= citalopram; S-cit = S-citalopram; fluox = fluoxetine.
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improvement in the dragging of the paws (Supplementary
Fig. 5A) and limited effects on exploratory activity
(Supplementary Fig. 5B), grip strength (Supplementary
Fig. 5C) and hindlimb tonus (Supplementary Fig. 5D), cita-
lopram treatment restored stride length to wild-type levels
at advanced stages of the trial (Fig. 5C). Moreover, treated
animals showed reduced tremors (Fig. 5D), reduced limb
clasping (Fig. 5E), and improved gait quality (Fig. 5F).
Citalopram treatment also resulted in a striking improve-
ment in balance and motor coordination as compared to
vehicle-treated CMVMJD135 mice. In the balance beam
walk test, we observed major improvements in the 12mm
square beam from 20 to 34 weeks of age (Fig. 6A and
Supplementary Video 1) and also in a wider (17mm)
round beam (Supplementary Fig. 5E). The most remarkable
beneﬁts of citalopram were observed in the motor swim-
ming test (Fig. 6B), since at many time points and until
quite late in the trial citalopram treated animals were in-
distinguishable from wild-type (Supplementary Video 2).
Overall, these results demonstrate that citalopram can
reduce the impairment in motor coordination of the
Machado-Joseph disease mouse, with less beneﬁt on
strength, suggesting effects at the level of the brainstem,
midbrain or cerebellum, rather than on spinocerebellar
tracts and muscle innervation. Treatment also signiﬁcantly
delayed disease progression in mice.
Citalopram treated wild-type mice behaved similarly to
their untreated littermates, conﬁrming the speciﬁcity of the
effect (Supplementary Fig. 6). Moreover, CMVMJD135
mice treated with a dosage of 13mg/kg showed more
limited improvements when compared to vehicle-treated
controls in all paradigms mentioned above
(Supplementary Fig. 7).
The analysis of brain tissue from CMVMJD135 mice
showed that citalopram treatment (8mg/kg) mitigated re-
active astrogliosis (Fig. 6C) and decreased ATXN3 intra-
nuclear inclusions in the brainstem (Fig. 6D), analogous to
the reduction of neuronal aggregates in C. elegans. This
reduction was observed in the pontine nuclei, reticuloteg-
mental nuclei of pons and facial motor nuclei of
CMVMJD135-treated mice when compared to their ve-
hicle-treated counterparts (Fig. 6D); the impact of citalo-
pram was less marked in the lateral reticular nuclei. This
reduced ATXN3 aggregation did not correspond to lower
levels of ATXN3 protein levels in the brainstem (Fig. 6E),
suggesting that the effect of citalopram in mice is similar to
that in C. elegans, affecting folding and stability of ATXN3
rather than clearance of the mutant protein. Citalopram
treatment also had neuroprotective effects, rescuing loss
of ChAT-positive motor neurons in the facial motor
nuclei (Fig. 7A). The same trend was observed for motor
neurons of the ventral horn of the lumbar spinal cord
(Fig. 7B), albeit without statistical signiﬁcance, in agree-
ment with the observed phenotypic effects upon treatment.
The mild reduction in Calbindin D28-K-positive cells seen
in the cerebellar cortex of CMVMJD135 mice was also
circumvented by citalopram treatment (Fig. 7C).
Figure 4 CMVMJD135 mice show normal levels of 5-HT
and 5-HT metabolic turn over at fully symptomatic stages
of disease. Levels of 5-HT, 5-HIAA and 5-HT turnover (5-HIAA/5-
HT) were measured by HPLC (A) in the cerebellum (n = 5 wild-
type; n = 7 CMVMJD135), (B) medulla oblongata (n = 6 wild-type;
n = 8 CMVMJD135) and (C) substantia nigra (n = 5 wild-type; n = 5
CMVMJD135) at 24 weeks of age. Data presented as the
mean  SEM. P4 0.05 (Student’s t-test). TO = turnover;
WT = wild-type.
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Discussion
In this study we describe a small molecule screen using a
collection of FDA/EMA-approved drugs to identify modu-
lators of neuronal dysfunction in transgenic C. elegans ex-
pressing mutant ATXN3. By using two model systems, we
combined the ease and speed of screening in C. elegans, the
ability to use genetics and selected small molecule agonists
and antagonists of receptors and transporters to validate
pathways, and the relevance of subsequent conﬁrmation
in a vertebrate model of Machado-Joseph disease. This
led to the identiﬁcation of neuroactive compounds,
among which modulators of the serotonergic pathway
that strongly suppressed Machado-Joseph disease patho-
genesis in vivo. In support of this screening strategy,
many of the suppressors of ATXN3 pathogenesis identiﬁed
in our study have been shown to be effective in other neu-
rodegenerative disorders, including Parkinson’s and
Alzheimer’s disease, and also in Machado-Joseph disease
(Clarke et al., 1966; Perenyi et al., 1985; Kanai et al.,
Figure 5 Impact of citalopram treatment at 8mg/kg on the neurological deficits of CMVMJD135 mice. (A) Schematic repre-
sentation of the preclinical therapeutic trial. Significant differences observed between vehicle (n = 13) and citalopram-treated CMVMJD135 mice
(n = 16) in (B) body weight (P = 0.001, 20–34 weeks) and (C) stride length (P = 0.015, 30 weeks). (D) Tremors, (E) limb clasping and (F) gait were
evaluated from 18 to 34 weeks of age with phenotype amelioration from 22 to 34 weeks of age. (n = 13–16,  SD), *P5 0.05, **P5 0.01 and
***P5 0.001 (Mann-Whitney U-test for non-parametric variables and ANOVA, Tukey correction for continuous variables). cit = citalopram.
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Figure 6 Citalopram treatment ameliorates balance and motor coordination and suppresses mutant ATXN3 aggregation in
Machado-Joseph disease mice. Significant differences observed between vehicle (n = 13) and citalopram-treated CMVMJD135 mice (n = 16) in
the (A) square beam (P5 0.001, 20–34 weeks) and (B) motor swimming (P5 0.001, 14–34 weeks) tests. (C) Immunohistochemistry and
quantification of GFAP-positive cells per area in substantia nigra from wild-type, vehicle- and citalopram-treated CMVMJD135 mice (n = 5 per
group, 34 weeks). (D) Neuronal inclusions in the pontine nuclei, reticulotegmental nucleus of the pons, facial motor nucleus and lateral reticular
nucleus of vehicle and citalopram-treated CMVMJD135 mice (n = 4, 34 weeks). (E) Brainstem immunoblots and quantification of total human
ATXN3 protein from vehicle and citalopram-treated CMVMJD135 mice (n = 5, 34 weeks). Data presented as mean  SEM, *P5 0.05 and
**P5 0.01 [ANOVA, Tukey correction (A and B) and one-way ANOVA (C–E)]. Scale bars = 20 mm. cit = citalopram; WT = wild-type; SN =
substantia nigra; PN = pontine nuclei; RtTg = reticulotegmental nuclei of pons; 7N = facial motor nuclei; LRt = lateral reticular nuclei.
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2003; Cho et al., 2009; Cirrito et al., 2011). A more in-
depth understanding of the mechanism of action of these
suppressors of expanded ATXN3 toxicity and their ability
to modulate aggregation offers new opportunities for small-
molecule therapeutics for Machado-Joseph disease and
other protein conformational diseases.
Citalopram and other SSRIs suppressed Machado-Joseph
disease pathogenesis in the C. elegans and mouse
models, showing beneﬁcial effects on motility/coordination,
aggregation of mutant ATXN3, and disease progression.
MOD-5 (and SERT) inhibition by citalopram likely results
in increased extracellular 5-HT levels and enhanced seroto-
nergic neurotransmission that can elicit 5-HT dependent
effects on neuronal activities, adaptation (Blier and de
Montigny, 1999; El Mansari et al., 2005; Schilstrom
et al., 2011), and remodelling (Musazzi et al., 2010;
Bessa et al., 2013). Indeed, ablation of the postsynaptic
receptor SER-1 (Hamdan et al., 1999), which is pharmaco-
logically similar to the mammalian 5-HT2 receptor, aggra-
vated ATXN3 pathogenesis. The beneﬁcial action of
citalopram required SER-1, suggesting that the downstream
effects of this drug are mediated by signalling cascades
involving this receptor. Furthermore, ablation of SER-4,
which shares similarity to vertebrates’ 5-HT1 autorecep-
tors, rescued motor neuron dysfunction and reduced
ATXN3 aggregation in vivo.
The therapeutic effects of SSRIs for amelioration of
mutant ATXN3-mediated neurotoxicity in both C. elegans
and mice required chronic treatment; likewise, citalopram
prolonged treatment is necessary in depression (Blier and de
Montigny, 1999). Such SSRI treatment modalities result in
5-HT1A autoreceptor desensitization (Blier and De
Figure 7 Citalopram treatment shows neuroprotective effects in CMVMJD135 mice. (A) Immunohistochemistry and quantification
of ChAT-positive cells per total area in the facial motor nucleus from wild-type, vehicle and citalopram-treated CMVMJD135 mice (n = 4 per
group, 34 weeks). (B) Immunohistochemistry and quantification of ChAT-positive cells per total area in the lumbar region of the ventral
horn of the spinal cord (LSC) from wild-type, vehicle and citalopram-treated CMVMJD135 mice (n = 3–4 per group, 34 weeks). (C)
Immunohistochemistry and quantification of Calbindin D28K-positive Purkinje cells per total area in the cerebellar cortex from wild-type, vehicle
and citalopram-treated CMVMJD135 mice (n = 4 per group, 34 weeks). Data presented as mean  SEM, *P5 0.05 and **P5 0.01 (one-way
ANOVA). Scale bars = 200 mm (A) and 100 mm (B and C). cit = citalopram; WT = wild-type; 7N = facial motor nuclei; LSC = lumbar spinal cord;
CBX = cerebellar cortex.
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Montigny, 1983; Lanfumey et al., 2008), which inactivates
the negative feedback mechanism taking place in presynap-
tic neurons, thereby increasing 5-HT availability and acti-
vating postsynaptic receptors (Lanfumey and Hamon,
2004). Pindolol, a b-adrenergic receptor partial agonist
with 5-HT1A receptor antagonist properties, when com-
bined with SSRIs, results in a signiﬁcant decrease in time
to ﬁrst response compared with SSRIs alone. Moreover, a
faster desensitization of 5-HT1A autoreceptors by a direct
agonist (e.g. buspirone) may also accelerate the therapeutic
efﬁcacy of SSRIs (Blier and Ward, 2003). Consistently,
targeting 5-HT autoreceptors by chronic treatment amelio-
rated mutant ATXN3-mediated pathogenesis in C. elegans.
Serotonin receptors in nematodes and mammalians, while
homologous, may not be functionally identical
(Komuniecki et al., 2004); therefore, it would be important
to identify the speciﬁc 5-HT receptors required for citalo-
pram’s effect on toxicity and aggregation of mutant
ATXN3 in mice.
In Huntingdon’s disease mouse models, SSRI treatment
resulted in striatal and memory preservation and extended
survival (Lauterbach, 2013). Citalopram has also been
shown to be beneﬁcial in models of Alzheimer’s disease
and in healthy human volunteers by reducing amyloid-b
in the CSF (Cirrito et al., 2011; Sheline et al., 2014). The
need for chronic and early symptomatic treatment in
Machado-Joseph disease suggests a neuroprotective mech-
anism rather than immediate effects on signalling cascades
(Sheline et al., 2014) or correction of an imbalance of 5-HT
in Machado-Joseph disease mice. Moreover, the effect of
citalopram and MOD-5 inactivation on aggregation
ATXN3 is consistent with an impact of serotonergic neuro-
transmission on the rebalance of proteostasis state of the
organism. Indeed, it has been recently described that the
release of serotonin from neurons signals to distal tissues
the activation of protective mechanisms to prevent proteo-
toxicity (Tatum et al., 2015).
Comparing the effects obtained with citalopram with
those described in the literature for other molecules with
positive effect in Machado-Joseph disease models, this SSRI
appears to have a higher therapeutic efﬁcacy. From our
own work, when we compare the current results with the
previous ﬁndings for the Hsp90 inhibitor 17-DMAG (Silva-
Fernandes et al., 2014), we observe a more pronounced
therapeutic effect of citalopram. Namely, the manifestation
of motor swimming defects was delayed 8 weeks by
17-DMAG treatment versus at least 20 weeks by citalo-
pram treatment; also, at 30 weeks, the percentage of
effect of 17-DMAG in this test was 33%, and that of cita-
lopram was 79%. The difference in performance between
the treated groups (normalized to the respective non-treated
groups) in the two experiments was statistically signiﬁcant
at this age (P = 0.018).
In conclusion, the efﬁcacy of citalopram in suppression of
ATXN3 pathogenesis in two disease models, as well as its
safety record of being widely used in depression patients,
prompts us to suggest this drug for clinical trials in patients
with Machado-Joseph disease.
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